Artwork
iconShare
 
Manage episode 333078086 series 3264057
Content provided by Practicing Clinicians Exchange. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Practicing Clinicians Exchange or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode, Sandip Patel, MD shares his thoughts on optimizing immune checkpoint inhibitor (ICI) therapy in advanced non-small-cell lung cancer (NSCLC) and discusses best practices for individualizing therapy decisions and managing adverse events.

Topics include:

  • Currently approved ICIs
  • Role of biomarker and PD-L1 testing in advanced NSCLC
  • Strategies to individualize ICI treatment for patients with advanced NSCLC
  • Strategies for identifying and managing immune-related adverse events in patients treated with ICI

Presenter:
Sandip P. Patel, MD
Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California – San Diego
La Jolla, California

Link to full program:
https://bit.ly/39vuCHC


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

  continue reading

90 episodes